What are the lasting impacts of RSV, and how can you prevent your infant from getting the infection? Dr. Stephania Cormier is ...

Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.

Despite 50 years of research, there are currently no RSV vaccines approved or in Phase III trials for any of the target populations. High levels of neutralizing antibodies to RSV F protein have ...

The vaccines, given in a single dose, stimulate the immune system to produce antibodies to protect against severe RSV infections and complications (e.g., pneumonia). The Centers for Disease ...

Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...

Robust immune responses were observed among healthy and high-risk younger adults who received the Ad26/protein RSV preF vaccine.

HealthDay News — For immunocompromised individuals, antibody response ... rise in preF immunoglobulin G (IgG) at 4 weeks. Overall, 139 participants reported RSV vaccination during the study ...

AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections. The antibody ...

New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting ...

There are currently no approved treatments for the underlying RSV infection," said John Whelan, president and chief executive officer of Inhalon Biopharma. "Inhalon’s inhaled antibody treatment ...

Future Virology. 2014;9(8):753-767. CHF: Congestive heart failure; CLD: Chronic lung disease; F: Fusion; G: Glyco; GLA-SE: Glucopyranosyl lipid A-stable emulsion; GMT ...